Charles River Labs (CRL) Issues Solid Q4 Results; Reaffirms FY12 Outlook
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $295.19 +1.28%
Financial Fact:
Selling, general and administrative: 85.65M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Selling, general and administrative: 85.65M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Charles River Laboratories International, Inc. (NYSE: CRL) reported Q4 EPS of $0.69, $0.13 better than the analyst estimate of $0.56. Revenue for the quarter came in at $291 million versus the consensus estimate of $282.76 million.
Charles River Laboratories International, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Charles River Laboratories International, Inc. (CRL) click here.
Charles River Laboratories International, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Charles River Laboratories International, Inc. (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
